The Use of Single-Beat TE-e' in Evaluation of Left Atrial Pressure in Critically Ill Patients: The TELAP-ICU Trial (TELAP-ICU)

September 9, 2026 updated by: Wincy Wing-Sze Ng, Queen Mary Hospital, Hong Kong
This study evaluates a new single-beat echocardiographic technique (TE-e', the time difference between the onset of the mitral inflow E wave and the septal e' wave on tissue Doppler imaging) for estimating left atrial pressure (LAP) in critically ill patients, comparing it against the standard two-beat method. The goal is to determine whether the faster, single-beat method gives results as reliable as the conventional method, and whether it can help identify patients with elevated left atrial pressure without an invasive procedure.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Left atrial pressure (LAP) is an important measure in the care of critically ill patients but usually requires an invasive catheter to assess directly. Echocardiography offers a non-invasive alternative. One promising marker, TE-e' (the time difference between the onset of the mitral inflow E wave and the septal e' wave on tissue Doppler imaging), was recently incorporated into the 2025 American Society of Echocardiography (ASE) diastolic function guidelines. The conventional method for calculating TE-e' requires measurements from two separate heartbeats, introducing potential error from beat-to-beat heart rate variability - a common issue in the critically ill patients. This study assesses a novel single-beat method, in which both waveforms are captured on the same Doppler display within one cardiac cycle, eliminating that source of variability. Patients undergoing clinically indicated transthoracic echocardiography (TTE) in the Adult Intensive Care Unit of Queen Mary Hospital, Hong Kong will have TE-e' measured by both methods, along with other echocardiographic parameters associated with LAP, to evaluate correlation between the two methods and their relationship with clinically assessed LAP.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Hong Kong
      • Hong Kong, Hong Kong
        • Recruiting
        • Adult Intensive Care Unit, Queen Mary Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients admitted to Adult Intensive Care Unit requiring a TTE

Description

Inclusion Criteria:

  • Adult patients ≥18 years admitted to the QMH Adult Intensive Care Unit (AICU)
  • Requiring a transthoracic echocardiogram (TTE) as part of routine clinical care
  • TE-e' obtainable by both the conventional and the novel method

Exclusion Criteria:

  • Patients <18 years of age
  • Patients in atrial fibrillation
  • Patients with a poor TTE acoustic window
  • Patients in whom TE-e' is technically difficult to obtain or interpret by either method

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Single cohort
each patient serves as their own comparison - conventional vs. novel method measured within the same transthoracic echocardiography study
Diagnostic test: Echocardiography
Full echocardiogram performed on recruited patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Correlation between novel (single-beat) and conventional (two-beat) TE-e' values
Time Frame: At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)

Secondary Outcome Measures

Outcome Measure
Time Frame
Correlation between novel and conventional methods in obtaining septal e' and s' velocities - At time of index TTE
Time Frame: At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
Correlation between clinical evaluation of LAP and TE-e' value
Time Frame: At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
Correlation between other echocardiographic parameters of LAP (E/A ratio, LAVi, TR Vmax, lung ultrasound 6-point protocol) and TE-e' value
Time Frame: At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)
At the time of index TTE (single time point for each patient) during the course of ICU stay (from day 1 of ICU admission till ICU discharge, up to 1 month)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen Mary Hospital, Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

September 1, 2026

First Submitted That Met QC Criteria

September 9, 2026

First Posted (Actual)

September 15, 2026

Study Record Updates

Last Update Posted (Actual)

September 15, 2026

Last Update Submitted That Met QC Criteria

September 9, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UW 26-246

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe